CompletedN/Aketamine

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

Sponsored by University of Alabama at Birmingham

NCT ID
NCT01887990
Target Enrollment
18 participants
Start Date
2012-05
Est. Completion
2014-01

About This Study

This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression.

Conditions Studied

DepressionSuicidal Ideation

Interventions

  • Ketamine
  • placebo

Eligibility

Age:19 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

1. Age : 19-64
2. Significant suicidality score on the Columbia Suicide Severity Rating Scale (C-SSRS)
3. Willing and able to provide informed consent.
4. Individuals with current substance abuse are allowed

Exclusion Criteria:

1. Pregnant or lactating; women of reproductive potential must have a negative urine pregnancy test (urine dipstick method)
2. Post-Partum state : defined as being within 2 months of delivery or miscarriage
3. Homicide risk as determined by clinical interview
4. Treatment with any medication known to specifically target the glutamate-NMDA receptor system (ie lamotrigine, acamprosate, memantine, riluzole or lithium)
5. Any known hypersensitivity or serious adverse effect associated with ketamine treatment.
6. Any clinically significant medical condition or therapy that would preclude treatment with ketamine, to include recent myocardial infarction or unstable angina
7. Medically unstable, including acute withdrawal from alcohol or benzodiazepines requiring the use of benzodiazepine treatment.
8. Any of the following DSM-IV diagnoses or categories:

   * Any current psychosis or history of a non-mood psychotic disorder (e.g., schizophrenia)
   * Currently in a manic or mixed episode
   * Current use (defined by urine dipstick test) or abuse of hallucinogenic drugs (except marijuana) such as phencyclidine
   * Any dissociative disorder
   * Any pervasive developmental disorder (e.g., autism)
   * A cognitive disorder (e.g., Alzheimer's Disease)
   * Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster B and C personality disorders may be included
   * Any eating disorder

Study Locations (1)

University of Alabama Birmingham
Birmingham, Alabama, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion | Huxley